Bionano GenomicsBNGOW 64 Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review. Among 315 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 317460% on this metric.
As of today (2026-06-29), the Forward Annual Dividend Yield of Bionano Genomics is 0.00%.
As of today (2026-06-29), the Trailing Annual Dividend Yield of Bionano Genomics is 0.00%.
BNGOW's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.06 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Bionano Genomics Forward Dividend Yield % Related Terms
BNGOW vs UEEC, CUPR, FEMY: Forward Dividend Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Bionano Genomics (BNGOW) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bionano Genomics and its competitors. According to the industry distribution chart, Bionano Genomics ranks #999999 out of 315 companies in the Medical Devices & Instruments industry.
Is Bionano Genomics' Forward Dividend Yield % too high?
Bionano Genomics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Bionano Genomics ranks #999999 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Forward Dividend Yield % compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #999999 out of 315 companies for Forward Dividend Yield %. This places Bionano Genomics in the lower half of its industry. The industry median Forward Dividend Yield % is 2.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.06, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 